

Identity:

Title: MD PhD
 Family Name(s): Mullens
 First Name(s): Wilfried
 Age: 49

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

President-Elect

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Ziekenhuis Oost Limburg Genk – University Hasselt, Belgium
Department:	Cardiology
Address:	Schiepse Bos 6
Post code / Zip:	3600 Genk
Country:	Belgium

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Degree

- Degree of Medical Doctor (1999), Acute Medicine (2002), Cardiologist (2005), Heart Failure and Cardiac Rehabilitation Specialist (2006) in Belgium.
- Advanced fellow in Heart Failure and Cardiac Transplantation (2007) Cleveland Clinic, Ohio, USA.
- Clinical Scholar in Electrical Therapies for Heart Failure (2008) Cleveland Clinic, Ohio, USA.
- Degree of Doctor of Philosophy (PhD) at the Technical University Eindhoven, the Netherlands (2009).

Professional appointments

- Staff Cardiologist in the Hospital Oost-Limburg Genk, Belgium since 2008.
- Professor in the School of Medicine and Life Sciences in University Hasselt, Belgium since 2008.
- Board member and President (2013-2016) of the Belgian Working Group on Heart Failure.
- Board member of HFA since 2018.
- Nucleus member of the ESC Cardiovascular Round Table since 2023.
- Editorial board of key heart failure journals (Eur J Heart Fail, Journal of Cardiac Failure, Acta Cardiologica).
- Writing committee member and reviewer of ESC Heart Failure, Cardiac Pacing and Diabetes Guidelines and HRS/APHRS/LAHRs Cardiac Physiologic Pacing Guidelines.
- Faculty member of the Post Graduate Course in Heart Failure in Zürich and London (University Zürich) since 2015.

Research

- H index 54 (> 330 peer-reviewed manuscripts, > 20 book chapters).
- Principal investigator of numerous investigator-initiated trials.
- Promotor/primary supervisor of > successful 10 Phd students since 2010.
- National coordinator, Steering committee member and member of DSMB for international RCTs.

- Part of several national and international research consortia.

Selection of 10 publications last 5 years (1st or last Author)

1. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study. *Circ Heart Fail* 2024 Jan;17(1):e011105.
2. Treating iron deficiency in heart failure. *N Engl J Med* 2023;389(11):1041-1042
3. Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial. *Eur Heart J* 2023;44(22):1995-2005.
4. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. *N Engl J Med* 2022;387(13):1185-1195.
5. Education and certification on heart failure of the HFA. *Eur J Heart Fail* 2022;24(2):249-253.
6. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following CRT -the IRON-CRT trial. *Eur Heart J* 2021;42(48):4905-4914.
7. Optimized implementation of CRT: a call for action for referral and optimization of care: A joint position statement from the HFA, EHRA, and EACVI of the ESC. *Eur J Heart Fail* 2021;22(12):2349-2369.
8. Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy. *J Am Coll Cardiol* 2020;75(12):1426-1438.
9. The use of diuretics in heart failure with congestion - a position statement from the HFA. *Eur J Heart Fail* 2019;21(2):137-155.
10. Dermal Interstitial Alterations in Patients With Heart Failure and Reduced Ejection Fraction: A Potential Contributor to Fluid Accumulation? *Circ Heart Fail* 2018;11(7):e004763.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society
150 words maximum

1. Board Member of HFA since 2018, key contributions:
 - Coordinator of the study group on cardiorenal dysfunction (2018-2022).
 - Coordinator of the device committee (2020-2022).
 - Deputy on certification (2020-2022).
 - Course director of the HFA Clinical Practice Update Course (2021-2023).
 - Faculty member of many HFA endorsed teaching courses.
 - Congress chair (2022-2024).
 - First author of seven position statements.
2. Reviewer / writing committee member of the Heart Failure (2016+2021+2023), Cardiac Pacing and CRT (2021) and Diabetes guidelines (2023) of ESC.
3. Nucleus member of the ESC Cardiovascular Round Table since 2023.
4. Part of editorial board European Journal of Heart Failure and reviewer for several ESC journals
5. Writer of several book chapters of ESC textbooks on heart failure, cardiac devices and acute cardiac care.
6. Invited speaker during HFA, EHRA, EACVI, ESC, ACC, AHA, HFSA, Middle East HF, and numerous (inter)national congresses / educational activities.
7. Board member since 2010 and President (2013-2016) of the Belgian Working Group on Heart Failure.

8. Board member of the Belgian Society of Cardiology 2013-2016.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

It is my sincere belief that by leading the extraordinary HFA Board I can help achieve the goals of the HFA by improving quality of life and longevity of heart failure patients, through better prevention, diagnosis and treatment. I will strive to guide the Association in a collegial manner and continue to act as a role model, maintaining the behavioral standards expected of the role. Major aims would be to improve the educational portfolio for all HF care-givers (not limited to cardiologists) and I believe that education should be linked with certification and quality of care. This will also require continuous updates to the HF curriculum, and collaboration with universities at the national level to create novel advanced heart failure training programs. I wish to continue to promote more engagement of young physicians, improve the gender balance at all levels of the Association. I will also aim to stimulate and execute international collaborative translational and clinical research of direct relevance to patients and to provide opportunities for young doctors and allied health professionals to enter research programs. As part of this the HFA must continuously invest in thorough collaboration with peers and other scientific cardiac organizations. The ultimate target of teaching, research, and recognition through certification and accreditation, is to raise standards in care facilities and enthuse the staff working in them and thereby improve HF care worldwide. Finally, more HF advocacy while collaborating with patient representatives at the local, national and European level should enable HFA to prepare for the exponentially growing needs of HF care in the immediate future.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

I appreciate the workload, importance and commitment that comes with the role of president-elect. I will significantly reduce my daily clinical and research time to be able to devote my energies to the HFA for the required consecutive years.